Makena (Hydroxyprogesterone Caproate Injection) Information

Why It Matters

The withdrawal removes the only FDA‑approved therapy for preventing preterm birth, reshaping obstetric care and signaling stricter scrutiny of accelerated approvals that lack confirmed clinical benefit.

Key Takeaways

• FDA proposed withdrawing Makena after confirmatory trial showed no benefit.
• Committee hearing held Oct 17‑19 2022 to assess clinical evidence.
• Makena was the only FDA‑approved drug to prevent preterm birth.
• Patients and providers advised to discontinue use pending alternative therapies.
• Confirmatory study was four times larger than original approval trial.

Pulse Analysis

Preterm birth remains a leading cause of neonatal morbidity and mortality in the United States, prompting regulators to fast‑track potential interventions. In 2011, the FDA granted Makena accelerated approval based on a surrogate endpoint—a reduction in deliveries before 37 weeks—hoping to address a critical public‑health gap. The drug quickly became the sole FDA‑approved option for women with a history of spontaneous preterm birth, positioning Covis Pharma as a niche market leader in obstetric therapeutics.

The pivotal shift occurred when a post‑marketing confirmatory trial, enrolling nearly four times the participants of the original study, failed to demonstrate any improvement in infant outcomes or a statistically significant decrease in preterm birth rates. This negative result triggered CDER’s October 2020 proposal to withdraw Makena’s approval, a move formalized through a public hearing in October 2022. The advisory committee examined the trial’s methodology, subgroup analyses—including Black women—and concluded that the drug’s risks outweighed unproven benefits, recommending removal from the market while a new study is contemplated.

Clinicians now face the immediate task of transitioning patients off Makena, and insurers must adjust formularies accordingly. For pharmaceutical firms, the case underscores the heightened accountability tied to accelerated pathways: without robust post‑market evidence, approvals can be rescinded, eroding market share and investor confidence. Researchers are also prompted to explore alternative progestogen formulations or entirely new mechanisms to fill the therapeutic void, while regulators may tighten criteria for surrogate‑based approvals to safeguard patient safety and ensure genuine clinical value.